Table 2

Percent achievement and odds ratios for LDL-C, non-HDL-C and Apo B targets
All subjects High risk or very high risk subjects
Week 6 Week 12 Week 6 Week 12
Targets E + A10 A20 OR E + A10 A20/A40 OR E + A10 A20 OR E + A10 A20/A40 OR
(mmol/L) for LDL-C, non-HDL-C; g/L for Apo B
Canadian (N = 515) (N = 515) (N = 516) (N = 509)
Single
LDL-C ≤2.0 62.3 31.1 3.67* 60.5 49.7 1.55*
non-HDL-C ≤2.6 62.3 35.9 2.95* 58.5 49.7 1.43*
Apo B ≤0.8 47.7 31.1 2.02* 44.6 38.1 1.31*
Dual/Triple
LDL-C ≤2.0, non-HDL-C ≤2.6 57.1 25.4 3.90* 53.1 44.2 1.43*
LDL-C ≤2.0, Apo B ≤1.0 45.2 21.6 2.99* 41.7 35.2 1.32*
LDL-C ≤2.0, non-HDL ≤2.6, Apo B ≤0.8 44.8 20.6 3.12* 41.3 34.8 1.32*
EU-High Risk (N = 515) (N = 515) (N = 516) (N = 516) (n = 66) (n = 67) (n = 67) (n = 67)
Single
LDL-C <2.5 85.2 72.6 2.18* 82.4 77.0 1.39* 68.2 50.7 2.08* 61.2 61.2 1.00
non-HDL-C <3.3 86.2 78.1 1.76* 84.1 81.9 1.17 68.2 59.7 1.45 68.7 70.1 0.93
Apo B <1.0 78.3 69.5 1.59* 74.8 71.5 1.18 58.7 48.5 1.51 53.8 53.0 1.03
Dual/Triple
LDL-C <2.5, non-HDL-C <3.3 83.9 70.3 2.20* 81.0 74.3 1.48* 66.7 50.7 1.94 61.2 58.2 1.13
LDL-C <2.5, Apo B <1.0 76.3 63.6 1.84* 72.8 67.8 1.27 55.6 40.9 1.81 49.2 50.0 0.97
LDL-C <2.5, non-HDL <3.3, Apo B <1.0 75.9 63.0 1.85* 72.6 67.2 1.29 55.6 40.9 1.81 49.2 50.0 0.97
EU-Very High Risk (N = 515) (N = 515) (N = 516) (N = 516) (n = 449) (n = 448) (n = 449) (n = 442)
Single
LDL-C <1.8 47.4 17.9 4.14* 43.6 32.2 1.63* 50.8 20.1 4.10* 47.2 35.3 1.64*
Non-HDL-C <2.6 62.3 35.9 2.95* 58.5 49.7 1.43* 66.1 39.7 2.96* 62.6 52.5 1.51*
Apo B <0.8 45.4 28.0 2.13* 43.8 35.4 1.43* 48.9 30.8 2.15* 46.9 37.7 1.46*
Dual/Triple
LDL-C <1.8, non-HDL-C <2.6 45.4 15.1 46.7* 41.3 30.1 1.64* 48.8 17.4 4.52* 45.0 32.8 1.68*
LDL-C <1.8, Apo B <0.8 38.7 14.4 3.75* 35.2 25.9 1.56* 41.4 16.3 3.64* 38.1 28.2 1.57*
LDL-C <1.8, non-HDL <2.6, Apo B <0.8 38.3 13.6 3.93* 35.2 25.7 1.57* 41.0 15.6 3.75* 38.1 28.0 1.59*

N may vary slightly between measured parameters due to differences in available data.

*OR considered significant based on associated 95% confidence interval which excludes 1.

A 10/20, atorvastatin 10 or 20 mg; Apo, apolipoprotein; AVD, atherosclerotic vascular disease; Canadian, Canadian Cardiovascular Society guidelines (2012); E, ezetimibe 10 mg; EU, European Guidelines (2012); LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; OR, odds ratio.

Constance et al.

Constance et al. Lipids in Health and Disease 2014 13:13   doi:10.1186/1476-511X-13-13

Open Data